CytoAgents
May 2, 2023
Share
This life sciences company is developing a drug designed to treat cytokine release syndrome (CRS) and recently raised $7 million in funding. It also recently received FDA approval to begin the next phase of its clinical trial to treat CRS in lymphoma patients receiving CAR T-cell therapy.